CRISPR-X Trademark
Trademark Overview
On Thursday, December 18, 2025, a trademark application was filed for CRISPR-X with the United States Patent and Trademark Office. The USPTO has given the CRISPR-X trademark a serial number of 99555280. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, June 1, 2026. This trademark is owned by CRISPR Therapeutics AG. The CRISPR-X trademark is filed in the Computer & Software Services & Scientific Services category with the following description:
Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development in the field of gene editing, delivery and formulation; medical research laboratory services; scientific laboratory services; custom cell-line engineering services for scientific research purposes; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell t...
General Information
| Serial Number | 99555280 |
| Word Mark | CRISPR-X |
| Filing Date | Thursday, December 18, 2025 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Monday, June 1, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 23, 2026 |
Trademark Statements
| Goods and Services | Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development in the field of gene editing, delivery and formulation; medical research laboratory services; scientific laboratory services; custom cell-line engineering services for scientific research purposes; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals |
| Pseudo Mark | CRISPER X |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, December 18, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | CRISPR Therapeutics AG |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 25 - NOT AVAILABLE |
| Address | ZUG V8 6300
CH |
Trademark Events
| Event Date | Event Description |
| Thursday, December 18, 2025 | NEW APPLICATION ENTERED |
| Thursday, December 18, 2025 | APPLICATION FILING RECEIPT MAILED |
| Thursday, April 9, 2026 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, April 21, 2026 | ASSIGNED TO EXAMINER |
| Tuesday, April 28, 2026 | NON-FINAL ACTION WRITTEN |
| Tuesday, April 28, 2026 | NON-FINAL ACTION E-MAILED |
| Tuesday, April 28, 2026 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, May 18, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, May 18, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, May 18, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, May 22, 2026 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, May 22, 2026 | EXAMINERS AMENDMENT E-MAILED |
| Friday, May 22, 2026 | EXAMINER'S AMENDMENT ENTERED |
| Friday, May 22, 2026 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, May 22, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
